The extreme effectiveness of frontline BEP chemotherapy makes it nearly impossible to replace. This forces novel drug development into the small, refractory patient population. This niche market makes it economically challenging for pharmaceutical companies to invest in large-scale trials, thus slowing innovation for new agents.

The fear of toxicity pushes many companies to pursue the same few well-validated targets, leading to an average of nine assets per target. This hyper-competition not only crowds the market but, more importantly, leaves vast patient populations without effective options because their diseases lack these "popular" targets.

The standard approach to reducing cancer drug toxicity is narrowing the target to specific mutations (e.g., HER2, KRAS). While this improves safety, it drastically shrinks the addressable patient population for each new therapy. This puts immense pressure on the pharmaceutical business model, where development costs average $2.5 billion per drug.

Evolutionary modeling shows that taking antibiotics beyond symptom resolution can be counterproductive. It needlessly kills off susceptible bacteria, creating a perfect environment for resistant strains to flourish. The optimal strategy is often to stop once the immune system can handle the rest, contrary to decades of medical advice.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

Investors are hesitant to fund antimicrobial resistance research because the field has been stuck for decades trying the same approaches—traditional antibiotics and vaccines—and expecting different results. A fundamental shift in scientific strategy is required to regain investor confidence and make progress against superbugs.

Developing an antibiotic is costly, but its use is short-term and new drugs are held in reserve, making them unprofitable. This market failure, not a lack of scientific capability, has caused pharmaceutical companies to exit the space, creating a worsening global health crisis.

MIT Professor Jim Collins estimates a $20 billion investment could fund the R&D and clinical trials for 15-20 new antibiotics, solving the crisis for decades. This cost is a fraction of recent tech investments, framing an existential threat as a solvable, relatively affordable problem.

The AI-discovered antibiotic Halicin showed no evolved resistance in E. coli after 30 days. This is likely because it hits multiple protein targets simultaneously, a complex property that AI is well-suited to identify and which makes it exponentially harder for bacteria to develop resistance.